Darbepoetin in chronic kidney disease and dialysis patients; an updated review of outcomes

Individuals with chronic renal failure in stage three and after demonstrate anemia as a frequent complication. Although target hemoglobin levels remain debatable in pre-dialysis and dialysis patients, correction of anemia with erythropoiesis-stimulating agents (ESAs) has resulted in reduced need for...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tarun Kumar Jeloka, Datta Jayanta, Suresh Babu Vallamkonda, Sujeet Narayan Charugulla, Gupta Namita
Formato:	article
Lenguaje:	EN
Publicado:	Society of Diabetic Nephropathy Prevention 2020
Materias:	anemia blood transfusions chronic kidney disease darbepoetin alfa erythropoiesis stimulating agents Therapeutics. Pharmacology RM1-950 Diseases of the genitourinary system. Urology RC870-923
Acceso en línea:	https://doaj.org/article/d275bea20fd24c25bdd81d04447f67e9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d275bea20fd24c25bdd81d04447f67e9
record_format	dspace
spelling	oai:doaj.org-article:d275bea20fd24c25bdd81d04447f67e92021-11-17T08:13:31ZDarbepoetin in chronic kidney disease and dialysis patients; an updated review of outcomes2345-420210.34172/npj.2020.14https://doaj.org/article/d275bea20fd24c25bdd81d04447f67e92020-05-01T00:00:00Zhttps://jnephropharmacology.com/PDF/npj-2295https://doaj.org/toc/2345-4202Individuals with chronic renal failure in stage three and after demonstrate anemia as a frequent complication. Although target hemoglobin levels remain debatable in pre-dialysis and dialysis patients, correction of anemia with erythropoiesis-stimulating agents (ESAs) has resulted in reduced need for blood transfusions, improved survival and enhanced overall quality of life. Owing to longer half-life and greater biological activity, darbepoetin alfa can maintain stable hemoglobin levels at extended dosing intervals. It is also economical and convenient with no compromise in efficacy. Studies have shown similar dose requirements for both intravenous versus subcutaneous darbepoetin in pre-dialysis and dialysis patients. This review article focuses on clinical outcomes of darbepoetin including the achieved hemoglobin target, maintenance of hemoglobin levels, all-cause mortality, cardiovascular events, additional blood transfusion, quality of life, and economic outcomes in patients with chronic kidney disease (CKD). This review also outlines the risk associated with darbepoetin administration and changes in guidelines recommendation for improving its use.Tarun Kumar JelokaDatta JayantaSuresh Babu VallamkondaSujeet Narayan CharugullaGupta NamitaSociety of Diabetic Nephropathy Prevention articleanemiablood transfusionschronic kidney diseasedarbepoetin alfaerythropoiesis stimulating agentsTherapeutics. PharmacologyRM1-950Diseases of the genitourinary system. UrologyRC870-923ENJournal of Nephropharmacology, Vol 9, Iss 2, Pp e14-e14 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	anemia blood transfusions chronic kidney disease darbepoetin alfa erythropoiesis stimulating agents Therapeutics. Pharmacology RM1-950 Diseases of the genitourinary system. Urology RC870-923
spellingShingle	anemia blood transfusions chronic kidney disease darbepoetin alfa erythropoiesis stimulating agents Therapeutics. Pharmacology RM1-950 Diseases of the genitourinary system. Urology RC870-923 Tarun Kumar Jeloka Datta Jayanta Suresh Babu Vallamkonda Sujeet Narayan Charugulla Gupta Namita Darbepoetin in chronic kidney disease and dialysis patients; an updated review of outcomes
description	Individuals with chronic renal failure in stage three and after demonstrate anemia as a frequent complication. Although target hemoglobin levels remain debatable in pre-dialysis and dialysis patients, correction of anemia with erythropoiesis-stimulating agents (ESAs) has resulted in reduced need for blood transfusions, improved survival and enhanced overall quality of life. Owing to longer half-life and greater biological activity, darbepoetin alfa can maintain stable hemoglobin levels at extended dosing intervals. It is also economical and convenient with no compromise in efficacy. Studies have shown similar dose requirements for both intravenous versus subcutaneous darbepoetin in pre-dialysis and dialysis patients. This review article focuses on clinical outcomes of darbepoetin including the achieved hemoglobin target, maintenance of hemoglobin levels, all-cause mortality, cardiovascular events, additional blood transfusion, quality of life, and economic outcomes in patients with chronic kidney disease (CKD). This review also outlines the risk associated with darbepoetin administration and changes in guidelines recommendation for improving its use.
format	article
author	Tarun Kumar Jeloka Datta Jayanta Suresh Babu Vallamkonda Sujeet Narayan Charugulla Gupta Namita
author_facet	Tarun Kumar Jeloka Datta Jayanta Suresh Babu Vallamkonda Sujeet Narayan Charugulla Gupta Namita
author_sort	Tarun Kumar Jeloka
title	Darbepoetin in chronic kidney disease and dialysis patients; an updated review of outcomes
title_short	Darbepoetin in chronic kidney disease and dialysis patients; an updated review of outcomes
title_full	Darbepoetin in chronic kidney disease and dialysis patients; an updated review of outcomes
title_fullStr	Darbepoetin in chronic kidney disease and dialysis patients; an updated review of outcomes
title_full_unstemmed	Darbepoetin in chronic kidney disease and dialysis patients; an updated review of outcomes
title_sort	darbepoetin in chronic kidney disease and dialysis patients; an updated review of outcomes
publisher	Society of Diabetic Nephropathy Prevention
publishDate	2020
url	https://doaj.org/article/d275bea20fd24c25bdd81d04447f67e9
work_keys_str_mv	AT tarunkumarjeloka darbepoetininchronickidneydiseaseanddialysispatientsanupdatedreviewofoutcomes AT dattajayanta darbepoetininchronickidneydiseaseanddialysispatientsanupdatedreviewofoutcomes AT sureshbabuvallamkonda darbepoetininchronickidneydiseaseanddialysispatientsanupdatedreviewofoutcomes AT sujeetnarayancharugulla darbepoetininchronickidneydiseaseanddialysispatientsanupdatedreviewofoutcomes AT guptanamita darbepoetininchronickidneydiseaseanddialysispatientsanupdatedreviewofoutcomes
_version_	1718425830658408448

Darbepoetin in chronic kidney disease and dialysis patients; an updated review of outcomes

Ejemplares similares